Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors

E. Havránková, V. Garaj, Š. Mascaretti, A. Angeli, Z. Soldánová, M. Kemka, J. Motyčka, M. Brázdová, J. Csöllei, J. Jampílek, CT. Supuran

. 2021 ; 23 (1) : . [pub] 20211226

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22011637

Grant support
MUNI/A/1202/2020 INGA MU, with the support of the Specific University Research Grant, as provided by the Ministry of Edu-cation, Youth and Sports of the Czech Republic in the year 2020
APVV-18-0302 Slovak Research and Development Agency

A series of 1,3,5-triazinyl aminobenzenesulfonamides substituted by aminoalcohol, aminostilbene, and aminochalcone structural motifs was synthesized as potential human carbonic anhydrase (hCA) inhibitors. The compounds were evaluated on their inhibition of tumor-associated hCA IX and hCA XII, hCA VII isoenzyme present in the brain, and physiologically important hCA I and hCA II. While the test compounds had only a negligible effect on physiologically important isoenzymes, many of the studied compounds significantly affected the hCA IX isoenzyme. Several compounds showed activity against hCA XII; (E)-4-{2-[(4-[(2,3-dihydroxypropyl)amino]-6-[(4-styrylphenyl)amino]-1,3,5-triazin-2-yl)amino]ethyl}benzenesulfonamide (31) and (E)-4-{2-[(4-[(4-hydroxyphenyl)amino]-6-[(4-styrylphenyl)amino]-1,3,5-triazin-2-yl)amino]ethyl}benzenesulfonamide (32) were the most effective inhibitors with KIs = 4.4 and 5.9 nM, respectively. In addition, the compounds were tested against vancomycin-resistant Enterococcus faecalis (VRE) isolates. (E)-4-[2-({4-[(4-cinnamoylphenyl)amino]-6-[(4-hydroxyphenyl)amino]-1,3,5-triazin-2-yl}amino)ethyl]benzenesulfonamide (21) (MIC = 26.33 μM) and derivative 32 (MIC range 13.80-55.20 μM) demonstrated the highest activity against all tested strains. The most active compounds were evaluated for their cytotoxicity against the Human Colorectal Tumor Cell Line (HCT116 p53 +/+). Only 4,4'-[(6-chloro-1,3,5-triazin-2,4-diyl)bis(iminomethylene)]dibenzenesulfonamide (7) and compound 32 demonstrated an IC50 of ca. 6.5 μM; otherwise, the other selected derivatives did not show toxicity at concentrations up to 50 μM. The molecular modeling and docking of active compounds into various hCA isoenzymes, including bacterial carbonic anhydrase, specifically α-CA present in VRE, was performed to try to outline a possible mechanism of selective anti-VRE activity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011637
003      
CZ-PrNML
005      
20220506130923.0
007      
ta
008      
220425s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms23010231 $2 doi
035    __
$a (PubMed)35008657
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Havránková, Eva $u Department of Chemical Drugs, Faculty of Pharmacy, Masaryk University, Palackého 1-3, 612 42 Brno, Czech Republic
245    10
$a Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors / $c E. Havránková, V. Garaj, Š. Mascaretti, A. Angeli, Z. Soldánová, M. Kemka, J. Motyčka, M. Brázdová, J. Csöllei, J. Jampílek, CT. Supuran
520    9_
$a A series of 1,3,5-triazinyl aminobenzenesulfonamides substituted by aminoalcohol, aminostilbene, and aminochalcone structural motifs was synthesized as potential human carbonic anhydrase (hCA) inhibitors. The compounds were evaluated on their inhibition of tumor-associated hCA IX and hCA XII, hCA VII isoenzyme present in the brain, and physiologically important hCA I and hCA II. While the test compounds had only a negligible effect on physiologically important isoenzymes, many of the studied compounds significantly affected the hCA IX isoenzyme. Several compounds showed activity against hCA XII; (E)-4-{2-[(4-[(2,3-dihydroxypropyl)amino]-6-[(4-styrylphenyl)amino]-1,3,5-triazin-2-yl)amino]ethyl}benzenesulfonamide (31) and (E)-4-{2-[(4-[(4-hydroxyphenyl)amino]-6-[(4-styrylphenyl)amino]-1,3,5-triazin-2-yl)amino]ethyl}benzenesulfonamide (32) were the most effective inhibitors with KIs = 4.4 and 5.9 nM, respectively. In addition, the compounds were tested against vancomycin-resistant Enterococcus faecalis (VRE) isolates. (E)-4-[2-({4-[(4-cinnamoylphenyl)amino]-6-[(4-hydroxyphenyl)amino]-1,3,5-triazin-2-yl}amino)ethyl]benzenesulfonamide (21) (MIC = 26.33 μM) and derivative 32 (MIC range 13.80-55.20 μM) demonstrated the highest activity against all tested strains. The most active compounds were evaluated for their cytotoxicity against the Human Colorectal Tumor Cell Line (HCT116 p53 +/+). Only 4,4'-[(6-chloro-1,3,5-triazin-2,4-diyl)bis(iminomethylene)]dibenzenesulfonamide (7) and compound 32 demonstrated an IC50 of ca. 6.5 μM; otherwise, the other selected derivatives did not show toxicity at concentrations up to 50 μM. The molecular modeling and docking of active compounds into various hCA isoenzymes, including bacterial carbonic anhydrase, specifically α-CA present in VRE, was performed to try to outline a possible mechanism of selective anti-VRE activity.
650    _2
$a antibakteriální látky $x farmakologie $7 D000900
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a karboanhydrasa I $x antagonisté a inhibitory $7 D024401
650    _2
$a karboanhydrasa II $x antagonisté a inhibitory $7 D024402
650    _2
$a karboanhydrasa IX $x antagonisté a inhibitory $7 D000071231
650    _2
$a inhibitory karboanhydras $x farmakologie $7 D002257
650    _2
$a karboanhydrasy $x účinky léků $7 D002256
650    _2
$a HCT116 buňky $7 D045325
650    _2
$a lidé $7 D006801
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a simulace molekulární dynamiky $7 D056004
650    _2
$a nádory $x farmakoterapie $7 D009369
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a sulfonamidy $x farmakologie $7 D013449
650    _2
$a enterokoky rezistentní vůči vankomycinu $x účinky léků $7 D065507
655    _2
$a časopisecké články $7 D016428
700    1_
$a Garaj, Vladimír $u Department of Pharmaceutical chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 832 32 Bratislava, Slovakia $1 https://orcid.org/000000028229414X
700    1_
$a Mascaretti, Šárka $u Czech Advanced Technology and Research Institute, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic
700    1_
$a Angeli, Andrea $u Section of Farmaceutical and Neutraceutical Sciences, Neurofarba Department, University of Florence, 50019 Sesto Fiorentino, Italy $1 https://orcid.org/0000000214707192
700    1_
$a Soldánová, Zuzana $u Department of Molecular Pharmacy, Faculty of Pharmacy, Masaryk University, Palackého 1-3, 612 42 Brno, Czech Republic
700    1_
$a Kemka, Miroslav $u Department of Pharmaceutical chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 832 32 Bratislava, Slovakia
700    1_
$a Motyčka, Jozef $u Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University, Odbojarov 10, 832 32 Bratislava, Slovakia
700    1_
$a Brázdová, Marie $u Department of Molecular Pharmacy, Faculty of Pharmacy, Masaryk University, Palackého 1-3, 612 42 Brno, Czech Republic
700    1_
$a Csöllei, Jozef $u Department of Chemical Drugs, Faculty of Pharmacy, Masaryk University, Palackého 1-3, 612 42 Brno, Czech Republic
700    1_
$a Jampílek, Josef $u Department of Chemical Biology, Faculty of Science, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic $u Institute of Neuroimmunology, Slovak Academy of Sciences, Dúbravska Cesta 9, 845 10 Bratislava, Slovakia $1 https://orcid.org/0000000320039052 $7 xx0027075
700    1_
$a Supuran, Claudiu T $u Section of Farmaceutical and Neutraceutical Sciences, Neurofarba Department, University of Florence, 50019 Sesto Fiorentino, Italy $1 https://orcid.org/0000000342620323
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 23, č. 1 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35008657 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130915 $b ABA008
999    __
$a ok $b bmc $g 1789311 $s 1162835
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 23 $c 1 $e 20211226 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a MUNI/A/1202/2020 $p INGA MU, with the support of the Specific University Research Grant, as provided by the Ministry of Edu-cation, Youth and Sports of the Czech Republic in the year 2020
GRA    __
$a APVV-18-0302 $p Slovak Research and Development Agency
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options